Overview

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19. This study is expected to enroll up to 84 patients with mild to moderate symptoms divided into each of the two study arms. Clinical outcomes of the two treatment arms will be compared. This study will be conducted virtually/remotely.
Phase:
Phase 2
Details
Lead Sponsor:
Northwell Health
Collaborator:
Cold Spring Harbor Laboratory
Treatments:
Famotidine